Velositol,
does it really help with Amplified muscle protein synthesis from protein and increased muscle?
research showsVelositol is rated C because a 10-person acute crossover trial found a higher four-hour muscle fractional synthesis rate when 2 g was added to a suboptimal 6-g whey dose than with whey alone. The sample was extremely small, the biopsy measure was an acute surrogate, and the branded-ingredient trial was funded by Nutrition 21. In a 35-person eight-week resistance-training trial, every group increased muscle size and fat-free mass, but the Velositol group had no additional body-composition or muscle-size benefit over protein controls. The gap between acute MPS and actual long-term hypertrophy, together with single-brand and manufacturer-funded evidence, yields C with 45 points.
ads claimMarketing turns twice the MPS, twice the protein effect, and more muscle with less protein from a relative change in a 10-person, four-hour, 6-g-whey condition into a long-term hypertrophy guarantee. The same amplification has not been established with an adequate 20-to-40-g high-quality protein dose.
Useful facts when choosing a product
- Velositol is a Nutrition 21 branded combination of amylopectin and trivalent chromium forms. Research on generic amylopectin or chromium cannot automatically be treated as evidence for this exact product.
- The acute human study added 2 g Velositol to a deliberately suboptimal 6-g whey dose. The same relative effect has not been established with a protein-rich meal or a 20-to-40-g protein serving.
- Blood, liver, and kidney markers generally stayed within clinical ranges in the eight-week trial, but 35 participants cannot establish long-term or rare safety. People with kidney or liver disease or using glucose-lowering or thyroid medicines should check chromium exposure with a clinician.
- Adequate total protein, leucine, and progressive resistance training are the primary conditions for hypertrophy. A branded additive does not replace them.
What the research actually shows
Ziegenfuss 2017 gave 10 healthy adults 6 g whey plus 2 g Velositol or 6 g whey in crossover periods and measured FSR for four hours after resistance exercise. The post-treatment independent t test was p=0.045, whereas ANCOVA was p=0.054, and Nutrition 21 supplied the ingredient and funding. Ziegenfuss 2021 randomized 35 men to 2 g Velositol plus 15 g whey, 15 g whey, or 30 g whey during eight weeks of training. Some muscular-endurance and jump measures were favorable, but between-group fat-free mass and muscle size did not differ, and the week-four net-protein-balance advantage was absent at week eight.
Why this is classified as C (45)
Stable-isotope acute MPS is a direct human surrogate, but the study had 10 participants, borderline statistics, manufacturer funding, and one branded ingredient. The only eight-week trial found some performance signals but no additional fat-free mass or muscle size. Separating the acute surrogate from long-term outcomes and applying the branded-ingredient C ceiling yields 45 points; chromium safety is a separate caution.
Counterpoint. Augmenting the acute response to a small protein dose may merit study in people who cannot consume enough protein. At present, meeting protein needs and using progressive resistance training are more reliable priorities for muscle gain.
Rejudgment record. New verdict — Accepted the n=10 acute MPS surrogate but applied the rule ① and ②-b C ceiling for borderline statistics, manufacturer-funded branding, and no additional muscle in the eight-week trial
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Acute amplification of muscle protein synthesis from low-dose whey | C | A manufacturer-funded n=10 trial was positive, but it used an acute biopsy surrogate with borderline statistics. |
| Long-term additional muscle gain | D | All groups improved in the eight-week trial, but Velositol produced no additional fat-free mass or muscle-size benefit. |
| Long-term strength and exercise-performance improvement | C | Some squat-repetition and jump outcomes were positive, but evidence comes from one small manufacturer-supported trial and is outcome-selective. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Ziegenfuss TN et al. 2017 | Randomized double-blind single-dose active-controlled crossover trial | 10 | Restricted grant and Velositol ingredient supplied by Nutrition 21 | Four-hour post-resistance-exercise muscle fractional synthesis rate | Six grams of whey plus 2 g Velositol produced a higher post-treatment FSR than 6 g whey, with p=0.045 or 0.054 depending on analysis. | Key acute human surrogate; very small |
| Ziegenfuss TN et al. 2021 | Eight-week randomized double-blind active-controlled resistance-training trial | 35 | Nutrition 21 funding and branded ingredient supplied | Fat-free mass, muscle size, strength, endurance, jump outcomes, whole-body protein balance, and safety | Some performance measures were positive, but there was no added fat-free mass or muscle size, and the net-protein-balance difference disappeared by week eight. | Direct limitation on long-term hypertrophy |
| NIH ODS Chromium fact sheet | Official safety and interaction evidence summary | United States National Institutes of Health | High-dose chromium risks, kidney and liver disease, and drug interactions | High supplemental exposure warrants caution in kidney or liver disease and can interact with some medicines. | Safety context, separate from efficacy |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-18 · Corrections: none
Cite this verdict
[Chamgap] Velositol x amplified muscle protein synthesis and increased muscle — Evidence Grade C·45. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/sports/velositol-amylopectin-chromium-muscle-protein-synthesis-growth/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.